

Hypertension Management: A Value of Information Perspective

Research Team:

Manaf Zargoush¹, Mehmet Gumus², Vedat Verter³, & Stella Daskalopoulou⁴

¹DeGroot School of Business, McMaster University, Canada

²Desautels Faculty of Management, McGill University, Canada

³Eli Board College of Business, Michigan State University, USA

⁴Faculty of Medicine, McGill University, Canada

Presentation:

Manaf Zargoush

Assistant Professor; Health Policy & Management

DeGroot School of Business

McMaster University

zargoush@mcmaster.ca



Agenda


- ✓ Background
- ✓ Problem Statement
- ✓ Methods (Prediction and Optimization)
- ✓ Results and Discussions



Hypertension (HTN)


- A chronic medical condition in which the blood pressure (BP) in vessels elevates to a level higher than its normal range.
 - ✓ major Public health issue worldwide;
 - ✓ highly prevalent with serious consequences (One billion in the world and $\frac{1}{3}$ in the US)

➤ Mechanism



Importance of HTN Control


The **leading risk for death** in North America (WHO)



77% of first stroke events occur among patients with HTN



treating **HTN**:



HTN Control

➤ **Good news**

- ✓ HTN can be controlled with promising benefits

➤ **Bad news**


- ✓ Only a few hypertensive patients have their BP under control
 - In the US, less than half of patients with HTN have it controlled!

Reasons for The Poor Control of HTN?

1. HTN is **asymptomatic**

✓ **silent killer**

✓ solution: keep track of BP



2. BP is complex; fluctuates both in the short- and long-terms.

✓ very difficult consistent and reliable measurement of BP.


3. Traditional BP measurement is **noisy**

✓ Obscuring the true underlying BP.



Solution:
increase the **accuracy** of:


- measurement
- predictions



4. 1,2,3 => profound **subjectivity** in clinical decision-making!

✓ physician inertia:

- *Physician's failure to adequately adjust treatment (i.e., add medication) in response to elevated BP*



“**humanistic**” issue related to “**physician behavior**”
or **judgment bias**
“**to err is human!**”

BP Measurements

➤ Measurement

1. Traditional approach (gold standard)


- ✓ peripheral BP
- ✓ noisy : *inaccurate*

2. New technologies

- ✓ e.g., tech. based on ultrasound
- ✓ Applanation Tonometry or Automated Office BP (AOBP)
- ✓ *noise-free or at least less noisy*
- ✓ more costly (staff, time, technology, etc.)



low adoption of these technologies
→ **uncertainty over their benefits vs cost!**



Value of Information (VOI)
comparing our best decisions:
in the presence and absence of information

HTN Control

1. Measurement

1. Systolic BP (SBP): usually on quarterly basis

2. Treatment

- Medication therapy through a class of medications called *antihypertensives*
- Usually combination therapy (i.e., multiple medications)



Five common classes of antihypertensives:

1. **Beta Blockers**
2. **ACEI** (Angiotensin-Converting-Enzyme Inhibitor)
3. **ARBs**: Angiotensin II Receptor Blockers
4. **Diuretic** (aka. thiazide)
5. **CCBs** (Calcium Channel Blockers)

Problem Statement

➤ How HTN can be controlled considering:

✓ **Measurement uncertainty**

- **underestimation vs. overestimation**

Learning (prediction)

✓ **Intervention trade-off**

- **Optimal course actions (medication therapy)**
- **too early (unnecessary medication side-effects) vs. too late (risk of CVD)**

Optimization

➤ **From analytics perspective**


➤ How to effectively marry **predictive analytics** and **prescriptive analytic** → **VOI?**




focus of today's presentation

How BP Evolves in the short- and long-term?

1. Everyone has a mean BP (θ_t): changes over time and **is unobservable** → basis for physician's medication decision
2. In the short-term (e.g., daily), one's **BP observation** (b_t) varies according to a Normal distribution with
 - ✓ mean = θ_t
 - ✓ variances = person's short-term BP variability (σ_b^2) + measurement noise (τ^2)
3. In the long-term (e.g., quarterly), θ_t changes according to a Normal distribution such that:
 - ✓ mean at $t + 1$ = mean at t + known/deterministic changes (such as change due to aging and medications)
 - ✓ variance = person's long-term BP variability (σ_θ^2)




The Framework for Prediction and Decision-Making



The Problem

Timeline of decision and events



Learning

Optimization

We model both to capture
the entire decision-making process

KF Learning

➤ KF characterized the parameters of belief about θ_t , i.e., $\pi_t^{KF}(\theta)$ as follows:

$$\begin{cases} \mu_t^{KF} = K_t b_t + (1 - K_t) \mu_{t-1}^{KF} \\ \sigma_{t,KF}^2 = (1 - K_t) \zeta_t \end{cases}$$

$$K_t = \frac{\zeta_t}{\phi^2 + \zeta_t}$$

$$\zeta_t = \sigma_{t-1,KF}^2 + \sigma_\theta^2$$

The weight we should assign to the new observation/evidence as opposed to the history/prior belief

- $K_t \in [0,1]$ is called *Kalman gain* which identifies the relative contribution of the new evidence b_t in building the new belief.
- new belief/prediction = convex combination of old prediction and the new observation
- does not account for any subjectivity (hence bias) in predictions

Surprise Induced Learning (SIL): a modified Bayesian updating!

➤ Conventional Bayesian Updating → very similar to KF!

$$\begin{aligned}\pi_t^B(\theta_t) &\equiv \pi_t^B(\theta) = \mathcal{N}(\mu_t^B, \sigma_{t,B}^2) \\ \begin{cases} \mu_t^B &= \rho_t \mathbf{b}_t + (1 - \rho_t) \mu_{t-1}^B \\ \sigma_{t,B}^2 &= (1 - \rho_t) \sigma_{t-1,B}^2 \end{cases} \\ \rho_t &= \frac{\sigma_{t-1,B}^2}{\sigma_{t-1,B}^2 + \phi^2}\end{aligned}$$

➤ The **issue**:

✓ Conventional Bayesian updating assumes **stationary mean** → **belief convergence!**



Not reacting to the new observation

SIL Strategy: a modified traditional Bayesian Updating!

➤ To resolve the **issue**:

✓ We introduce the notion of **surprise**, as:

$$s_t = \begin{cases} 1, & \text{if } |\mu_{t-1} - b_t| \geq \Delta \\ 0, & \text{otherwise} \end{cases}$$

difference between the prior belief and the new evidence (arrow pointing to $|\mu_{t-1} - b_t|$)

threshold for the expectedness of events (arrow pointing to Δ)

surprise ~ observing unexpected events




Signal for BP regimen change

When surprise occurs, we impose a shock to the belief/prediction system by resetting the belief updating mechanism such that:

- maximum belief uncertainty (we are in a surprise state)
- maximum weight to new observations → surprise triggers attention
- minimum weight to the prior belief

SIL Strategy



SIL Strategy

➤ Δ : characterizes the physician's learning behavior → physician's characteristics → **commitment to belief**

✓ physician with **low Δ** → **undercommitment to belief**

- experiences more frequent surprises,
- lower expectation for change → perceiving even small changes as unexpected,
- assigns larger weights to the new observations → **overestimating evidence**

✓ physician with **high Δ** → **overcommitment to belief**

- becomes surprised less frequently,
- higher expectations for change, → ignoring larger changes
- with time, she assigns higher weights to her own belief → **underestimating evidence**
- Captures the so-called **physician inertia** (a key obstacle in HTN treatment recently mentioned in the EU Guideline for HTN control)

➤ Both cases indicate **sub-optimal learning behaviors**.

Question: Is there an **optimal Δ** ? →

Answer: Yes! The one which minimizes prediction error or maximizes outcomes!

Data Setting at the Montreal General Hospital

➤ Two sets of data

1. Noise-Free Environment

- ✓ Patients undergoing meticulous BP measurements in the clinic
- ✓ Quarterly visits
- ✓ Using Automated Office Blood Pressure (AOBP) technology

2. Noisy Environment

- ✓ **For the same patient**
- ✓ At the same day of clinic visit
- ✓ Undergoing 24hr BP measurement, every 20-30min
 - Called 24hr BP measurement or Ambulatory BP Monitoring (ABPM)

Characterizing Optimal Decision Making Through Optimization

➤ Markov Decision Process (MDP)

- ✓ Choosing optimal medication decisions to maximize the expected quality adjusted life years of patients over the problem horizon

➤ Key component:

- ✓ **States**: information needed for making decisions and characterizing the evolution of system → patient's BP mean (either we know it or we learn it)

➤ Both learning strategies used in our study are Markovian, sequential, and recursive → ideal for MDP

➤ States in SIL strategy:

- ✓ Best prediction about patient's BP mean → μ_t^{SIL}
- ✓ Number of office visits since last surprise $n_t = \{0, 1, \dots, N\}$
 - one-to-one relationship to $\sigma_t^2!$
 - measures belief strength

surprise state

Optimization Framework

➤ We develop three MDP models:

Under Noise-Free Measurement:

1. Under noise-free measurement, called **MDP⁰**.




Under Noisy Measurement:

2. Under noisy measurement but KF learning strategy, called **MDP^{KF}**.
3. Under noisy measurement but SIL learning strategy, called **MDP^{SIL}**.

Optimal Policies for $MDP^{SIL}(\Delta^*)$

Theorem 5. Suppose that *As.1-4* - *As4-4* hold for $t = 1, 2, \dots, T$. Then, at each period t and for fixed levels of μ_t and \mathbf{m}_t , there exists an optimal policy $a_t^*(\mu_t, n_t, \mathbf{m}_t)$ which is nondecreasing in n_t . In other words, there is a threshold n_t^* such that:

$$a_t^*(\mu_t, n_t, \mathbf{m}_t) = \begin{cases} i^-, & n_t < n_t^* \\ i^+, & n_t \geq n_t^* \end{cases} \quad (4.25)$$



Value of Information (VOI) Analysis

➤ Definitions:

✓ v^0 : value function under perfect information (i.e., noise-free)

✓ v^l : value function under imperfection information, **learner l** (i.e., noisy)



$VOI = v^0 - v^l$: in terms of Total QALY gained

*Improvement in outcomes as a result of reducing uncertainty over θ_t
[max] price paid for reducing uncertainty over θ_t*

✓ Ratio of Value of Information (RVOI)

$RVOI = \frac{v^0 - v^l}{v^l}$: in terms of % Total QALY gained

VOI Decomposition : Important Lessons


➤ More specifically:

- ✓ v^0 : the value function under perfect information.
- ✓ v^{KF} : the value function under imperfect information, yet KF-learner (learning benchmark)
- ✓ v^* : the value function under imperfect information, yet Δ^* -learner
- ✓ v^l : the value function under imperfect information, yet $\Delta^{l \neq *}$ -learner

➤ Therefore:

$$VOI^l = v^0 - v^l = \overbrace{(v^0 - v^{KF})}^{KF \rightarrow \theta} + \overbrace{(v^{KF} - v^*)}^{\Delta^* \rightarrow KF} + \overbrace{(v^* - v^l)}^{\Delta^l \rightarrow \Delta^*}$$

price paid for **information**
(net value of information)
value of new technology
price paid for
optimal learning strategy
price paid for
optimal learning behavior



Conclusion:

- not all the price we pay is because of not knowing the truth (which can be learned/predicted),
- we also pay for our sub-optimal learning strategy (predictive models) or suboptimal learning behavior!

In our study: $VOI = VOI^l(\sigma_\theta, \sigma_b, \tau, j)$; **l:learner/physician, j:patient's baseline risk**

Conclusions:

- The new technology is valuable!
- Its value depends on:
 - ✓ **Patient:** risk profile and her BP variability
 - ✓ **Measurement technology:** current traditional devices
 - ✓ **Physician:** those who are not good learners pay more!
- Not all the price we pay for information (because of lack of knowledge) is because of the information itself (that we tend to know or predict); we also pay for our **suboptimal learning strategies** (predictive models) or **suboptimal learning behaviors**!

*not choosing the best
predictive models/methods*

*not using the predictive models
in the best possible way*

Thank You!